PARP1 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: TRAF3IP2-AS1, known as an N6-methlydenosine-related lncRNA, performed anti-tumor effects in NONO-TFE3 translocation renal cell carcinoma (NONO-TFE3 tRCC) by reducing the stability of PARP1 [poly (ADP-ribose) polymerase 1] and elevating the expression level of PTEN (phosphatase and tensin homolog) (Yang et al., 2021).